Use of aminoalkylbenzothiazepine derivatives

1. A method for treating non-alcoholic fatty liver disease (NAFLD) or dyslipidemia in a subject in need thereof, comprising administrating an effective amount of a pharmaceutical composition comprising a compound represented by Formula 1 below or a pharmaceutically acceptable salt thereof in the subject:

wherein

R 1 is hydroxy, carboxy, or hydroxysulfonyl(C 1-4 alkyl);

R 2 and R 3 are each independently hydrogen, C 1-4 alkyl, hydroxy(C 1-4 alkyl), carbamoyl(C 1-4 alkyl), carboxy, carboxy(C 1-4 alkyl), (C 5-10 heteroaryl)(C 1-4 alkyl) or (C 5-10 aryl)(C 1-4 alkyl), or R 2 and R 3 , taken together with the respective carbon atom to which they are attached, form C 3-7 cycloalkyl;

R 4 is hydrogen or carboxy(C 1-4 alkyl);

R 5 is hydrogen, halogen, (C 1-4 alkyl)thio, (C 1-4 alkyl)amino, or di(C 1-4 alkyl)amino;

R 6 and R 7 are each independently C 1-6 alkyl;

R 8 and R 9 are each independently hydrogen, hydroxy, C 1-4 alkoxy, C 1-4 alkyl, halogen, nitro, cyano, amino, (C 1-4 alkyl)amino, di(C 1-4 alkyl)amino, acetamido, formyl, C 1-4 alkanoyl, carboxy, carbamoyl, (C 1-4 alkyl)carbamoyl, di(C 1-4 alkyl)carbamoyl, carbamoyloxy, (C 1-4 alkyl)carbamoyloxy, di(C 1-4 alkyl)carbamoyloxy, (C 1-4 alkyl)sulfonyloxy, sulfamoyloxy, (C 1-4 alkyl)sulfamoyloxy, or di(C 1-4 alkyl)sulfamoyloxy;

Q is C 5-19 aryl or C 5-19 heteroaryl; and

n is an integer of 0 to 3.

2. The method of claim 1 ,

wherein

R 1 is hydroxy, carboxy, or hydroxysulfonyl(C 1-4 alkyl);

R 2 and R 3 are each independently hydrogen, C 1-4 alkyl, hydroxy(C 1-4 alkyl), carbamoyl(C 1-4 alkyl), carboxy, carboxy(C 1-4 alkyl), or (C 5-10 heteroaryl)(C 1-4 alkyl)), or R 2 and R 3 , taken together with the respective carbon atom to which they are attached, form C 3-7 cycloalkyl;

R 4 is hydrogen or carboxy(C 1-4 alkyl);

R 5 is (C 1-4 alkyl)thio, or di(C 1-4 alkyl)amino;

R 6 and R 7 are each independently C 1-6 alkyl;

R 8 and R 9 are each independently hydrogen, hydroxy, halogen, or C 1-4 alkoxy;

Q is C 5-10 aryl; and

n is an integer of 0 to 3.

3. The method of claim 1 , wherein R 1 is hydroxy, carboxy, or hydroxysulfonylmethyl.

4. The method of claim 1 , wherein R 2 and R 3 are each independently hydrogen, carboxy, methyl, isobutyl, carbamoylmethyl, carboxymethyl, carboxyethyl, hydroxymethyl, imidazolylmethyl, indolylmethyl or ethyl, or R 2 and R 3 , taken together with the respective carbon atom to which they are attached, form cyclopropyl.

5. The method of claim 1 , wherein R 4 is hydrogen, carboxymethyl, or carboxyethyl.

6. The method of claim 1 , wherein R 5 is methylthio, ethylthio, or dimethylamino.

7. The method of claim 1 , wherein R 6 and R 7 are both butyl or ethyl.

8. The method of claim 1 , wherein R 8 and R 9 are each independently hydrogen, hydroxy, methoxy, methyl, ethyl, fluoro, chloro, nitro, cyano, amino, methylamino, ethylamino, dimethylamino, acetyl, carboxy, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, carbamoyloxy, methylcarbamoyloxy, dimethylcarbamoyloxy, methylsulfonyloxy, sulfamoyloxy, methylsulfamoyloxy, or dimethylsulfamoyloxy.

9. The method of claim 1 , wherein Q is phenyl, pyridinyl, pyrimidinyl, or thiophenyl.

10. The method of claim 1 , wherein the compound is selected from the group consisting of:

2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)acetic acid;

3-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)propanoic acid;

2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)succinic acid;

(S)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)propanoic acid;

2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)pentanedioic acid;

4-amino-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)-4-oxobutanoic acid;

(R)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)propanoic acid;

2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)-2-methylpropanoic acid;

(R)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)-3-(1H-imidazol-4-yl)propanoic acid;

(R)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)-3-(1H-indol-2-yl)propanoic acid;

(S)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)-4-methylpentanoic acid;

(S)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)pentanedioic acid;

(S)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)-3-hydroxypropanoic acid;

3-((carboxymethyl)((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)propanoic acid;

3-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)pentanedioic acid;

2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)-2-oxoacetic acid;

1-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)cyclopropanecarboxylic acid;

2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)-2-oxoethanesulfonic acid;

2-(((3,3-dibutyl-5-(4-methoxyphenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)acetic acid;

2-(((3,3-dibutyl-5-(4-hydroxyphenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)acetic acid;

2-(((3,3-dibutyl-5-(3-methoxyphenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)acetic acid;

2-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)acetic acid;

2-(((3,3-dibutyl-5-(3-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)acetic acid;

2-(((3,3-dibutyl-5-(3-fluoro-4-methoxyphenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)acetic acid;

2-(((3,3-dibutyl-5-(4-methoxyphenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)-2-oxoethanesulfonic acid;

1-(((3,3-dibutyl-5-(3-fluoro-4-methoxyphenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)cyclopropanecarboxylic acid;

2-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)-2-oxoacetic acid;

(S)-2-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)propanoic acid;

(S)-2-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)-3-hydroxypropanoic acid; and

1-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)cyclopropanecarboxylic acid.

11. The method of claim 1 , wherein the non-alcoholic fatty liver disease comprises simple steatosis, steatohepatitis, or hepatocirrhosis.

12. The method of claim 1 , wherein the dyslipidemia comprises hyperlipidemia, hypercholesterolemia, or hypertriglyceridemia.

13. The method of claim 1 , wherein the pharmaceutical composition treats or ameliorates liver fibrosis.

14. The method of claim 1 , wherein the compound is 2-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)methyl)amino)acetic acid.

15. The method of claim 1 , wherein the pharmaceutical composition further contains a pharmaceutically acceptable carrier, diluent, or excipient.

16. The method of claim 1 , wherein the compound represented by Formula 1 or the pharmaceutically acceptable salt thereof is contained in an amount of 0.1 wt% to 75 wt% based on the total weight of the composition.

17. A method for treating or ameliorating non-alcoholic fatty liver disease (NAFLD) in a subject in need thereof, comprising administrating an effective amount of 2-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepi n-8-yl)methyl)amino)acetic acid or a pharmaceutically acceptable salt thereof in the subject.

18. A method for treating or ameliorating dyslipidemia in a subject in need thereof, comprising administrating an effective amount of 2-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepi n-8-yl)methyl)amino)acetic acid or a pharmaceutically acceptable salt thereof in the subject.